{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:13:31Z","timestamp":1793502811916,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R21MH094961"],"award-info":[{"award-number":["R21MH094961"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH096876"],"award-info":[{"award-number":["R01MH096876"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R25MH071584"],"award-info":[{"award-number":["R25MH071584"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["21DA030702-01A1"],"award-info":[{"award-number":["21DA030702-01A1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.biopsych.2015.08.021","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T09:23:37Z","timestamp":1440840217000},"page":"997-1005","source":"Crossref","is-referenced-by-count":123,"title":["Reduced Brain Cannabinoid Receptor Availability in Schizophrenia"],"prefix":"10.1016","volume":"79","author":[{"given":"Mohini","family":"Ranganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Cortes-Briones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halle","family":"Thurnauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Planeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Skosnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Labaree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Neumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toral","family":"Surti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Cyril","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2015.08.021_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00213-009-1591-7","article-title":"The endocannabinoid system as a target for modelling psychosis","volume":"206","author":"Koethe","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.08.021_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00213-009-1612-6","article-title":"Role of cannabis and endocannabinoids in the genesis of schizophrenia","volume":"206","author":"Fernandez-Espejo","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.08.021_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00406-009-0024-2","article-title":"Cannabis and psychosis\/schizophrenia: Human studies","volume":"259","author":"D\u2019Souza","year":"2009","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2015.08.021_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09540260902782802","article-title":"Cannabinoids and psychosis","volume":"21","author":"Sewell","year":"2009","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.biopsych.2015.08.021_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nrn2253","article-title":"Cannabis, the mind and society: The hash realities","volume":"8","author":"Murray","year":"2007","journal-title":"Nat Rev Neurosci"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2015.08.021_bib6","first-page":"S15","article-title":"[Behavioral, cognitive and psychophysiological effects of cannabinoids: Relevance to psychosis and schizophrenia]","volume":"32","author":"Sewell","year":"2010","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.biopsych.2015.08.021_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2015.08.021_bib8","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","article-title":"Elevated endogenous cannabinoids in schizophrenia","volume":"10","author":"Leweke","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.biopsych.2015.08.021_bib9","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.08.021_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis","volume":"194","author":"Koethe","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.08.021_bib11","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.2174\/138161212802884843","article-title":"Anandamide dysfunction in prodromal and established psychosis","volume":"18","author":"Leweke","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.biopsych.2015.08.021_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-511X-2-5","article-title":"Endocannabinoid signalling in the blood of patients with schizophrenia","volume":"2","author":"De Marchi","year":"2003","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.biopsych.2015.08.021_bib13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00221-006-0503-x","article-title":"Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia","volume":"172","author":"Newell","year":"2006","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.biopsych.2015.08.021_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12264-007-0051-9","article-title":"No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia","volume":"23","author":"Deng","year":"2007","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.biopsych.2015.08.021_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","article-title":"Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia","volume":"28","author":"Zavitsanou","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.08.021_bib16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-007-0660-5","article-title":"Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression","volume":"114","author":"Koethe","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.biopsych.2015.08.021_bib17","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/npp.2010.75","article-title":"Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder","volume":"35","author":"Eggan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.08.021_bib18","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","article-title":"Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia","volume":"65","author":"Eggan","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2015.08.021_bib19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","article-title":"Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: Effect of antipsychotic treatment","volume":"206","author":"Uriguen","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.08.021_bib20","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/npp.2011.43","article-title":"Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex","volume":"36","author":"Dalton","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.08.021_bib21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2012.07.021","article-title":"Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia","volume":"141","author":"Jenko","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2015.08.021_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","article-title":"Studies on [3H]CP-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use","volume":"103","author":"Dean","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2015.08.021_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2014.07.017","article-title":"Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia","volume":"159","author":"Volk","year":"2014","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2015.08.021_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000245220","article-title":"Risperidone treatment increases CB1 receptor binding in rat brain","volume":"91","author":"Secher","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.biopsych.2015.08.021_bib25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1017\/S1461145708008560","article-title":"The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: Implications for olanzapine-induced weight gain","volume":"11","author":"Weston-Green","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2015.08.021_bib26","doi-asserted-by":"crossref","first-page":"e33548","DOI":"10.1371\/journal.pone.0033548","article-title":"Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain","volume":"7","author":"Weston-Green","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2015.08.021_bib27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jnr.20630","article-title":"Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia","volume":"82","author":"Andersson","year":"2005","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.biopsych.2015.08.021_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000245220","article-title":"Risperidone treatment increases CB1 receptor binding in rat brain","volume":"91","author":"Secher","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.biopsych.2015.08.021_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00210-005-1074-2","article-title":"Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens","volume":"371","author":"Sundram","year":"2005","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.biopsych.2015.08.021_bib30","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.2174\/138161208786549380","article-title":"Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain","volume":"14","author":"Horti","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.biopsych.2015.08.021_bib31","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.neuroimage.2010.04.034","article-title":"Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR","volume":"52","author":"Wong","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2015.08.021_bib32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","article-title":"Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia","volume":"79","author":"Ceccarini","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2015.08.021_bib33","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","article-title":"Consensus nomenclature for in vivo imaging of reversibly binding radioligands","volume":"27","author":"Innis","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2015.08.021_bib34","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.neuroimage.2010.04.066","article-title":"Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: Test-retest reproducibility and gender differences","volume":"52","author":"Normandin","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2015.08.021_bib35","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00259-010-1426-0","article-title":"Approaches to quantify radioligands that wash out slowly from target organs","volume":"37","author":"Hirvonen","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.biopsych.2015.08.021_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation","volume":"7","author":"Kay","year":"1989","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.biopsych.2015.08.021_bib37","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/jcbfm.2015.46","article-title":"Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: Assessment of kinetic analysis methods, test-retest reproducibility, and gender differences","volume":"35","author":"Normandin","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2015.08.021_bib38","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/01.WCB.0000038000.34930.4E","article-title":"Strategies to improve neuroreceptor parameter estimation by linear regression analysis","volume":"22","author":"Ichise","year":"2002","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2015.08.021_bib39","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/mp.2013.61","article-title":"Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study","volume":"18","author":"Neumeister","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.08.021_bib40","first-page":"1689","article-title":"11C-JHU75528: A radiotracer for PET imaging of CB1 cannabinoid receptors","volume":"47","author":"Horti","year":"2006","journal-title":"J Nucl Med"},{"issue":"suppl 2","key":"10.1016\/j.biopsych.2015.08.021_bib41","first-page":"216","article-title":"Kinetic modeling of CB1 PET tracer [11C]OMAR in rhesus monkeys and humans","volume":"51","author":"Normandin","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2015.08.021_bib42","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1124\/jpet.107.130328","article-title":"Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol","volume":"324","author":"McKinney","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.08.021_bib43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0169-328X(96)00277-X","article-title":"Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions","volume":"46","author":"Romero","year":"1997","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.biopsych.2015.08.021_bib44","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1523\/JNEUROSCI.16-24-08057.1996","article-title":"Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain","volume":"16","author":"Sim","year":"1996","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2015.08.021_bib45","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/mp.2011.82","article-title":"Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers","volume":"17","author":"Hirvonen","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.08.021_bib46","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/adb.12116","article-title":"[F]MK-9470 PET measurement of cannabinoid CB receptor availability in chronic cannabis users","volume":"20","author":"Ceccarini","year":"2015","journal-title":"Addict Biol"},{"key":"10.1016\/j.biopsych.2015.08.021_bib47","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/j.1530-0277.2012.01815.x","article-title":"Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence","volume":"36","author":"Neumeister","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.biopsych.2015.08.021_bib48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fpsyt.2014.00054","article-title":"Gone to pot - A review of the association between cannabis and psychosis","volume":"5","author":"Radhakrishnan","year":"2014","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2015.08.021_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu Rev Psychol"},{"key":"10.1016\/j.biopsych.2015.08.021_bib50","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301643","article-title":"Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis","volume":"33","author":"D\u2019Souza","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.08.021_bib51","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00213-008-1422-2","article-title":"The effects of cannabinoids on serum cortisol and prolactin in humans","volume":"203","author":"Ranganathan","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.08.021_bib52","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/npp.2012.8","article-title":"Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Delta(9)-THC in humans","volume":"37","author":"D\u2019Souza","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.08.021_bib53","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/0269881108092393","article-title":"Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users","volume":"23","author":"Ramaekers","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2015.08.021_bib54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00008877-200209000-00018","article-title":"SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats","volume":"13","author":"Cohen","year":"2002","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2015.08.021_bib55","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev.pharmtox.47.120505.105354","article-title":"Non-nicotinic therapies for smoking cessation","volume":"47","author":"Siu","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.biopsych.2015.08.021_bib56","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0028-3908(02)00118-1","article-title":"Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence","volume":"43","author":"Castane","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2015.08.021_bib57","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12031-010-9340-2","article-title":"Influence of chronic nicotine administration on cerebral type 1 cannabinoid receptor binding: An in vivo micro-PET study in the rat using [18F]MK-9470","volume":"42","author":"Gerard","year":"2010","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.biopsych.2015.08.021_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0006-8993(02)03344-9","article-title":"Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine","volume":"954","author":"Gonzalez","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2015.08.021_bib59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2006.11.013","article-title":"Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats","volume":"557","author":"Marco","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.08.021_bib60","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0091-3057(95)00023-P","article-title":"Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol","volume":"51","author":"Romero","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2015.08.021_bib61","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/schbul\/sbp031","article-title":"Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis","volume":"36","author":"Koskinen","year":"2010","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2015.08.021_bib62","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0022-3565(24)37979-0","article-title":"Large receptor reserve for cannabinoid actions in the central nervous system","volume":"288","author":"Gifford","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.08.021_bib63","doi-asserted-by":"crossref","first-page":"9800","DOI":"10.1073\/pnas.0703472104","article-title":"[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor","volume":"104","author":"Burns","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2015.08.021_bib64","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/jcbfm.2015.46","article-title":"Imaging the cannabinoid CB1 receptor in humans with [C]OMAR: Assessment of kinetic analysis methods, test-retest reproducibility, and gender differences","volume":"35","author":"Normandin","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2015.08.021_bib65","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00213-006-0508-y","article-title":"The acute effects of cannabinoids on memory in humans: A review","volume":"188","author":"Ranganathan","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.08.021_bib66","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis","volume":"29","author":"D\u2019Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.08.021_bib67","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2015.08.021_bib68","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.biopsych.2005.01.003","article-title":"Defining a cognitive function decrement in schizophrenia","volume":"57","author":"Keefe","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.08.021_bib69","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1037\/0894-4105.12.3.426","article-title":"Neurocognitive deficit in schizophrenia: A quantitative review of the evidence","volume":"12","author":"Heinrichs","year":"1998","journal-title":"Neuropsychology"},{"key":"10.1016\/j.biopsych.2015.08.021_bib70","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction","volume":"57","author":"D\u2019Souza","year":"2005","journal-title":"Biol Psychiatry"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322315006861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322315006861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:48:47Z","timestamp":1748580527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322315006861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0006322315006861"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2015.08.021","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}